Skip to main content
ARTRYA LIMITED logo

ARTRYA LIMITED — Investor Relations & Filings

Ticker · AYA ISIN · AU0000182412 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2022-06-30 Director's Dealing
Country AU Australia
Listing ASX AYA

About ARTRYA LIMITED

https://artrya.com

Artrya Limited is a medical technology company focused on the development of artificial intelligence solutions for the detection and management of coronary artery disease. The company's flagship platform, Artrya Salix, utilizes deep learning algorithms to automate the analysis of Computed Tomography Coronary Angiography (CTCA) scans. This technology is designed to assist clinicians by identifying and quantifying key markers of heart disease, including coronary artery stenosis and high-risk vulnerable plaque, which are often difficult to detect through manual review. By providing rapid, non-invasive, and objective assessments, the platform aims to improve diagnostic accuracy, streamline clinical workflows, and support early intervention strategies for patients at risk of major adverse cardiac events. The software integrates into existing clinical environments to provide point-of-care decision support for radiologists and cardiologists.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - Bernie Ridgeway 3 pages 124.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the interest, and transaction details. This is a report of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document length is 4611 characters, and it contains detailed transaction data, not just an announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-06-30 English
Change of Director's Interest Notice - John Barrington 3 pages 124.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares before and after the change, nature of the change (off-market transfers), and dates. This is a formal notification of a director's personal share transactions. The document is not a financial report, earnings release, or management discussion, but a regulatory disclosure of insider trading activity by a director. Therefore, it fits the category 'Director's Dealing' (DIRS). The document length and content confirm it is the actual notice, not just an announcement or certification. Confidence is high due to clear matching of content to category definition.
2022-06-29 English
Change of Director's Interest Notice - Bernie Ridgeway 3 pages 124.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares before and after the change, dates of changes, and nature of the transactions. This is a formal notification of personal share transactions by a company director, which fits the definition of Director's Dealing filings. The document is not a financial report, earnings release, or management report, but a regulatory disclosure of insider trading activity.
2022-06-23 English
Artrya Appoints Accomplished American Physician as CMO 3 pages 453.8KB
Board/Management Information Classification · 95% confidence The document is an ASX market announcement dated 20 June 2022, regarding the appointment of a new Chief Medical Officer (CMO) for Artrya Limited. It details the professional background and qualifications of Dr. Jacob Agris and his role in the company. There is no financial data, no discussion of financial results, no regulatory filings related to financial performance, no voting results, no legal proceedings, no capital changes, and no mention of any report publication. The content is focused on management changes, specifically the appointment of a senior executive. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 6977 characters, which is consistent with a detailed announcement but not a full report. Confidence is high as the content clearly matches the MANG category.
2022-06-19 English
Conference Call - Update on US FDA Application 1 pa
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 June 2022, titled 'CONFERENCE CALL – UPDATE ON US FDA APPLICATION'. It announces an upcoming investor and analyst conference call to discuss the update on the US FDA application. The text includes details on how to join the call and contact information but does not contain any financial data, results, or detailed report content. The document is short (1657 characters) and serves as a notice for a conference call rather than the transcript or report itself. Therefore, it fits best under the category of Call Transcript (CT) announcements, but since it is only an announcement of the call and not the transcript, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general announcement that does not fit other categories.
2022-06-16 English
Update on US FDA Application for Artrya Salix 2 pages 119.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX market release dated 16 June 2022 providing an update on the US FDA application status for Artrya's Salix product. It discusses regulatory progress, clinical partnerships, and funding status but does not contain financial statements or detailed financial results. The document is relatively short (3941 characters) and serves as a regulatory and operational update rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is an announcement about regulatory and business developments, which aligns best with the Regulatory Filings (RNS) category, a fallback for miscellaneous regulatory and compliance announcements that do not fit other specific categories.
2022-06-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.